Cargando…

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuchel, Marina, Raal, Frederick J, Hegele, Robert A, Al-Rasadi, Khalid, Arca, Marcello, Averna, Maurizio, Bruckert, Eric, Freiberger, Tomas, Gaudet, Daniel, Harada-Shiba, Mariko, Hudgins, Lisa C, Kayikcioglu, Meral, Masana, Luis, Parhofer, Klaus G, Roeters van Lennep, Jeanine E, Santos, Raul D, Stroes, Erik S G, Watts, Gerald F, Wiegman, Albert, Stock, Jane K, Tokgözoğlu, Lale S, Catapano, Alberico L, Ray, Kausik K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314327/ https://www.ncbi.nlm.nih.gov/pubmed/37130090 http://dx.doi.org/10.1093/eurheartj/ehad197

Ejemplares similares

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
por: Cuchel, Marina, et al.
Publicado: (2014)

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
por: Wiegman, Albert, et al.
Publicado: (2015)

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease : Consensus Statement of the European Atherosclerosis Society
por: Nordestgaard, Børge G., et al.
Publicado: (2013)

Current Treatment Options in Homozygous Familial Hypercholesterolemia
por: Kayikcioglu, Meral, et al.
Publicado: (2022)

The landscape of preventive cardiology in Turkey: Challenges and successes
por: Tokgozoglu, Lale, et al.
Publicado: (2021)

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
por: Ramaswami, Uma, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic in patients with a previous history of premature myocardial infarction
por: Kayikcioglu, Meral, et al.
Publicado: (2020)

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
por: Raal, Frederick, et al.
Publicado: (2023)

Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations
por: Orringer, Carl E., et al.
Publicado: (2020)

Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases
por: Al Dubayee, Mohammed, et al.
Publicado: (2022)

A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting
por: Blom, Dirk J., et al.
Publicado: (2022)

Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia
por: Kayikcioglu, Meral, et al.
Publicado: (2020)

Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia
por: Kayikcioglu, Meral, et al.
Publicado: (2021)

Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review
por: Bruckert, Eric, et al.
Publicado: (2020)

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
por: Blom, Dirk J., et al.
Publicado: (2018)

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
por: Stroes, Erik S., et al.
Publicado: (2015)

The spoils of war and the long-term spoiling of health conditions of entire nations
por: Navarese, Eliano P., et al.
Publicado: (2022)

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
por: Ference, Brian A., et al.
Publicado: (2017)

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
por: Mach, François, et al.
Publicado: (2018)

Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
por: Olmastroni, Elena, et al.
Publicado: (2022)

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
por: Ginsberg, Henry N, et al.
Publicado: (2021)

Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms
por: Khoury, Etienne, et al.
Publicado: (2023)

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society
por: Roeters van Lennep, Jeanine E, et al.
Publicado: (2023)

Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study
por: de Boer, Lotte M, et al.
Publicado: (2022)

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia
por: Olmastroni, Elena, et al.
Publicado: (2023)

Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
por: Vuorio, Alpo, et al.
Publicado: (2021)

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
por: Borén, Jan, et al.
Publicado: (2020)

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement( )
por: Kronenberg, Florian, et al.
Publicado: (2022)

Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score
por: Moulin, Philippe, et al.
Publicado: (2018)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

CEPHEUS SA: a South African survey on the under-treatment of hypercholesterolaemia
por: Raal, Frederick Johan, et al.
Publicado: (2011)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Editorial: Rare dyslipidemias
por: Sadiq, Fouzia, et al.
Publicado: (2023)

ANMCO Position Paper: diagnostic–therapeutic pathway in patients with hypercholesterolaemia and statin intolerance
por: Gulizia, Michele Massimo, et al.
Publicado: (2017)

ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes
por: Colivicchi, Furio, et al.
Publicado: (2017)

Hypercholesterolaemia in a vegan.
por: Duggan, B., et al.
Publicado: (1997)

Nutraceuticals in hypercholesterolaemia: an overview
por: Santini, Antonello, et al.
Publicado: (2016)

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
por: Ben-Omran, Tawfeg, et al.
Publicado: (2019)

Integration of sex and gender in cardiovascular medicine: a scientific and clinical imperative
por: Kavousi, Maryam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0lt0gq9da8sk58eq9m7sufvuan